SOPHiA GENETICS SA - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on June 22, 2026, reports a significant capital raising event for SOPHiA GENETICS SA, a foreign private issuer based in Rolle, Switzerland. The filing details the completion of a public offering of ordinary shares during the month of June 2026.
Key Financial Metrics
- Gross Proceeds: Approximately $57.5 million.
- Shares Issued: 12,104,900 ordinary shares (par value CHF 0.05 per share).
- Offering Price: $4.75 per share.
- Over-Allotment: Included 1,578,900 shares purchased by underwriters pursuant to the full exercise of their option.
- Net Proceeds: The filing text does not provide a clear value for net proceeds after deducting underwriting discounts, commissions, and offering expenses.
- Debt and Liquidity: The filing text does not provide specific data on current debt levels, cash flow, or liquidity ratios.
Material Changes
The primary material change reported is the increase in share capital and cash reserves resulting from the equity offering. The offering closed on June 18, 2026, following the entry into an underwriting agreement on June 16, 2026, with TD Securities (USA) LLC as the representative.
Outlook, Risks, and Management Commentary
The filing confirms the successful execution of the offering under a registration statement on Form F-3. No specific forward-looking guidance, management commentary on future operations, or detailed risk factors are included in this specific report text, other than standard references to the underwriting agreement terms and customary representations.
Investor Verification Checklist
- Verify the exact amount of underwriting discounts and commissions to calculate net proceeds.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific use of proceeds and lock-up provisions.
- Confirm the impact of the new share issuance on existing shareholder dilution.
- Check subsequent filings for the actual deployment of the $57.5 million in gross proceeds.